Pharmaceutical Cartridges Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Pharmaceutical Cartridges Market Trends and Insights

Rising Demand for Self-Injection Pen and Wearable Injector Formats

Pen injectors and wearable pumps now anchor patient-centred treatment, letting individuals administer chronic therapies without clinic visits. Ypsomed sold over 12 million reusable pens and 1.7 billion prefilled pens in 2024, underscoring adoption scale. With roughly 500 million people living with type 2 diabetes and 1 billion affected by obesity, user-friendly devices that support frequent dosing have become essential. Clinical work shows subcutaneous injections up to 10 mL win 79% patient acceptance and pain returns to baseline within 30 minutes, so expanding cartridge volumes meets consumer comfort thresholds.^{[1]Wendy D. Woodley, “Clinical Evaluation of Large Volume Subcutaneous Injection Tissue Effects, Pain, and Acceptability in Healthy Adults,” Clinical and Translational Science, ascpt.onlinelibrary.wiley.com}Connected pens now log dosing data for adherence monitoring, turning delivery hardware into real-world evidence tools that strengthen pharma value propositions. The trend adds steady volume to the pharmaceutical cartridge market as home therapy shifts from exception to norm.

Shift of GLP-1 Obesity and High-Viscosity Biologics to Cartridge Delivery

GLP-1 receptor agonists have become the fastest-growing pharmaceutical class and their migration from diabetes into obesity care drives new cartridge orders. West Pharmaceutical Services secured multiyear elastomer deals chiefly aimed at this vertical, with self-injection products already forming 73% of its proprietary segment sales. To handle formulations thicker than 15 cP, BD partnered with Ypsomed to pair Neopak XtraFlow glass syringes with autoinjectors, ensuring smooth subcutaneous delivery. Patent reviews show 57% of GLP-1 filings address delivery mechanisms rather than molecules, revealing competitive moats that could slow generic erosion while keeping cartridge demand high. Reloadable autoinjectors are surfacing as greener, lower-cost alternatives, but they still rely on rugged cartridges engineered for multiple actuations. These developments are injecting urgency into capacity build-outs across the pharmaceutical cartridge market.

Emergence of Large-Volume Wearable On-Body Injector Cartridges (≥ 10 mL)

Wearable injectors unlock subcutaneous delivery of biologics previously relegated to intravenous infusions. Stevanato Group’s Vertiva 10 mL platform exemplifies this direction, matching extended delivery windows for high-dose therapeutics. Trials show 5 mL wearables achieve 93.2% localization in target tissue with strong user acceptance. Ultra-thin cannulas that widen the lumen by 30% cut delivery times for thick solutions, addressing viscosity challenges.^{[2]Bruce C. Roberts, “Novel Cannula Design Improves Large Volume Auto-Injection Rates for High Viscosity Solutions,” PubMed, pubmed.ncbi.nlm.nih.gov} Pipeline reviews list 182 large-volume subcutaneous biologics, with oncology doses often spanning 5-20 mL versus ≤ 5 mL for non-cancer use. Different dose bands demand specific cartridge geometries, reinforcing the need for versatile manufacturing lines within the pharmaceutical cartridge market.

EU MDR Annex 1 Sterility Rules Spurring RTU Cartridge Adoption

The 2023 Annex 1 revision broadened sterile-manufacturing guidance from 16 to 58 pages. Requirements for barrier technologies and Pre-Use Post-Sterilization Integrity Testing (PUPSIT) increase complexity for traditional wash-sterilize lines, prompting a shift to RTU cartridges that arrive sterile and ready for filling. RTU systems eliminate multiple processing stages, cut contamination risk, and boost line throughput.^{[3]Tina Morris, “PUPSIT and the Annex 1 Revision,” PDA, pda.org} A consortium between SCHOTT Pharma, Gerresheimer, and Stevanato Group aims to standardize RTU formats, reflecting collective recognition that regulatory pressure now favours pre-sterilized containers. As firms standardize global production on the most stringent rules, Annex 1 is indirectly lifting RTU adoption rates worldwide, adding premium value to the pharmaceutical cartridge market.

Complex Multi-Step Manufacturing and Stringent cGMP Validation

Cartridge fabrication requires precision tolerances for break-loose force, glide force, and plunger travel. USP <382> now mandates container-closure system testing rather than individual component checks, adding fresh validation layers. Development cycles can lengthen 12-18 months as each variable undergoes statistical validation. AI tools add transparency demands because regulators want algorithm logic alongside performance metrics. High-grade cleanrooms, barrier isolators, and validated depyrogenation ovens raise capital thresholds, deterring new entrants and slowing capacity additions within the pharmaceutical cartridge market.

Substitution Risk from Pre-Filled Syringes in ≤ 3 mL Range

Small-volume drugs may stay with syringes that offer lower unit costs and turnkey filling solutions. Therapies such as anticoagulants and growth hormones already use 1-3 mL syringes, and switching to cartridges offers limited clinical upside. Drug sponsors often prefer to leverage existing syringe lines rather than invest in fresh cartridge tooling unless viscosity or patient-centric features demand change, tempering growth for that capacity band.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Material: Glass Dominance Faces Engineering Plastics Challenge

Glass held 72.88% of overall pharmaceutical cartridge market share in 2025, reflecting decades of regulatory confidence and its inert, transparent nature. The segment benefits from broad line compatibility and ample legacy tooling across fill-finish sites. Engineering plastics, notably COC and COP, are rising at a 11.71% CAGR because they resist breakage and tolerate high-pH biology, advantageous for novel oncology agents. Regulatory endorsement arrived when TOPAS Advanced Polymers secured the first USP 661.1 compliance for cyclic olefins.

Pharmaceutical cartridge industry players invest in polymer lines that match glass output speeds, but glass suppliers reply with strengthened borosilicate such as SCHOTT EVERIC to cut cosmetic rejects. Oncology pipelines that require cryogenic storage lean toward polymer because its seal integrity outperforms glass at low temperatures. Sustainability debates add tension; polymers allow energy-lite molding, while glass touts proven recyclability. Competition will intensify as both camps market advanced coatings and siliconization upgrades to capture share within the pharmaceutical cartridge market.

By Delivery-Device Compatibility: Wearable Systems Disrupt Pen Dominance

Reusable pen injectors secured 43.55% of pharmaceutical cartridge market size in 2025, entrenched by decades of insulin therapy familiarity. Yet wearable on-body pumps are forecast to grow 10.98% CAGR through 2031 because they house 5–10 mL cartridges that deliver weekly GLP-1 or oncology biologics at home. BD Libertas wearable injectors proved subcutaneous delivery for agents up to 50 cP, confirming technical readiness.

Device makers now forge multi-supplier networks ensuring glass and elastomer fit across platforms, as Ypsomed coordinates more than 15 partners to secure global inventory. Gas-driven drivers and AI-monitored actuation force replace traditional springs to handle viscous drugs safely. Autoinjectors targeting 5.5 mL volumes arrive from Aktiv Medical Systems, pointing to higher-dose standards. These changes expand choice and lift the overall pharmaceutical cartridge market.

By Capacity: Large-Volume Cartridges Drive Innovation

Cartridges under 3 mL held 40.92% pharmaceutical cartridge market share in 2025 owing to long-standing diabetes and hormone products. The pharmaceutical cartridge market size for containers above 10 mL is predicted to rise at 9.86% CAGR because high-dose biologics now shift to subcutaneous wearables. Stevanato Group’s portfolio spans 5–50 mL, proving scale flexibility.

Clinical data show 10 mL injections meet tolerance thresholds when delivered over several minutes, so device makers optimize flow via ultra-thin cannulas. Larger cartridges demand stronger glass and refined silicon layers to prevent breakage during shipping. Filling lines adjust stopper insertion force and venting parameters for bigger internal volumes. These technical revisions support broader therapy scope and deepen penetration of large-format segments across the pharmaceutical cartridge market.

By Therapeutic Area: Oncology Growth Challenges Diabetes Leadership

Diabetes represented 24.08% of pharmaceutical cartridge market size in 2025, propelled by insulin and, increasingly, dual usage of GLP-1 agents for weight control. Oncology is poised for 14.12% CAGR, the fastest among all segments. Antibody-drug conjugates and checkpoint inhibitors now launch in high-concentration forms suitable for 5–10 mL cartridges, letting patients avoid infusion suites.

Immunology remains sizeable as adalimumab biosimilars reinforce self-administered models. Respiratory biologics targeting severe asthma, ophthalmic anti-VEGF treatments, and novel neurology injections further extend cartridge use. Polymer containers that tolerate cryogenic storage address gene and cell therapy vectors. As personalized medicine grows, precision-filled cartridges support micro-batch production, enhancing the pharmaceutical cartridge market outlook.

By End User: CMO Outsourcing Reshapes Manufacturing

Pharmaceutical companies commanded 59.05% of demand in 2025 through direct oversight of proprietary products and capacity investments. CMOs/CDMOs, however, show the strongest 11.32% CAGR as drug developers outsource sterile assembly to specialized partners. PCI Pharma Services allocated USD 365 million across US and EU sites for drug-device packaging.

Resilience plans to fill up to 200 million cartridges yearly by 2025 after its USD 225 million Cincinnati upgrade. Asia Pacific CDMOs attract volume through cost advantages and PIC/S GMP alignment, with Terumo expanding its cartridge assembly services. This outsourcing trend boosts flexibility, lifts smaller biotech launches, and supports sustained growth of the pharmaceutical cartridge market.

Geography Analysis

North America held 38.21% pharmaceutical cartridge market share in 2025 backed by heavy capital projects such as Novo Nordisk’s USD 4.1 billion fill-finish campus and SCHOTT Pharma’s USD 371 million polymer syringe plant in North Carolina. FDA encouragement of advanced manufacturing accelerates AI and modular isolator uptake, positioning the region as a global benchmark for next-gen production.

Europe follows closely owing to Annex 1 sterility reforms that push RTU adoption. Stevanato Group’s new Cisterna di Latina facility adds regional capacity for EZ-fill cartridges, aligning with the EU Critical Medicines Act that seeks supply-security via local output. Joint clinical-assessment rules and the forthcoming Health Technology Assessment Regulation unify demand, favouring suppliers with proven conformity across multiple markets.

Asia Pacific is forecast to grow 9.84% CAGR through 2031, the fastest worldwide. India’s Kapoor Glass exports 90% of its cartridge output to Western clients, underpinning the region’s cost-efficient manufacturing base. Regulatory harmonization through the Asia Partnership Conference of Pharmaceutical Associations sparks smoother cross-border approvals. Countries like South Korea and Singapore nurture biotech hubs, while China’s expanding biologics sector heightens need for high-quality containment. Collectively these initiatives cement Asia Pacific as a pivotal growth engine for the pharmaceutical cartridge market.

Regulatory Landscape

Sterile primary containers and their filling operations for pharmaceutical cartridges are shaped by GMP expectations, pharmacopeial material standards, and device-connection requirements. In Europe, the EU GMP Annex 1 revision that took effect in August 2023 has become a practical benchmark for cartridge-related aseptic processing, encouraging manufacturers to document Contamination Control Strategies (CCS) and increase use of barrier technologies and integrity-testing approaches such as PUPSIT. That regulatory convergence has also supported wider adoption of ready-to-use (RTU) cartridges.

Globally, standards bodies and regulators continue to tighten design and verification norms across container and closure systems. ISO released ISO 11040-8:2026 in 2026, covering requirements and test methods for finished prefilled syringes, which influences expectations for interacting components (barrels, plungers, closures) that are commonly shared across cartridge ecosystems. FDA guidance for glass systems also highlights the need for compatibility and connectivity testing beyond baseline dimensional standards, so ISO 11040-4 recognition does not eliminate product-specific verification. Connector standardization is likewise extending into adjacent transfer components around fill-finish, as West Pharmaceutical Services aligned Vial Adapter products with ISO 80369-7 in May 2026 to support traceability and safer connection practices across injection supply chains.

Value Chain Analysis

The pharmaceutical cartridge value chain begins with raw materials such as borosilicate glass tubing and engineered polymers including COP and COC, along with elastomer and rubber components. It then moves through forming and finishing (conversion, annealing, surface treatment or siliconization, and inspection), followed by cleaning and sterilization, or RTU preparation. As RTU offerings expand, more of the complexity shifts upstream to container suppliers that deliver pre-washed, depyrogenated, and sterile nests or tubs, allowing drug manufacturers and CDMOs to concentrate on aseptic filling, stoppering, inspection, and device assembly for pens, autoinjectors, and wearable systems.

Across the chain, qualification burden and change control are key governance points, since any material, process, or supplier change typically requires re-qualification with the drug sponsor under cGMP expectations and quality agreements. In 2026, West Pharmaceutical Services highlighted this balancing act through collaboration and portfolio reallocation: it renewed its technology exchange and cross-licensing agreement with Daikyo Seiko, Ltd. on July 14, 2026 for joint development spanning vials, cartridges, and syringes, and it transferred manufacturing and supply rights for the SmartDose 3.5 mL on-body delivery system effective July 1, 2026. Taken together, these actions show how cartridge suppliers manage access to innovation through licensing and co-development, while reallocating resources across delivery platforms, with CDMOs and device partners adding capacity and assembly nodes closer to end markets.

Market Opportunities and Future Outlook

Compliance-driven adoption of ready-to-use (RTU) cartridges remains a clear whitespace area, particularly as Annex 1-aligned aseptic expectations push manufacturers to reduce on-site preparation steps and human intervention. That shift changes purchasing decisions toward suppliers that can package RTU containers with validated sterility assurance, barrier-compatible formats, and change-control documentation, rather than competing primarily on unit pricing. Standardization work among major container suppliers, including industry efforts to harmonize RTU formats, also supports multi-site transfers for pharma and CDMOs and improves scalability across geographies.

A second opportunity cluster is multi-format sterile fill-finish capacity that supports cartridge manufacturing alongside syringes and vials. This fits how drug-device combination programs require flexible lines and validated component sets. In 2026, concrete investment and capacity signals include CDMO expansions aimed at cartridge-capable fill-finish, such as Grand River Aseptic Manufacturing’s USD 100 million expansion for filling syringes and cartridges, and Halo Pharma’s USD 30 million investment to add sterile vial, prefilled syringe, and cartridge manufacturing. On the supplier side, product development targeting complex biologics and device pairing continues to surface, including SCHOTT Pharma’s April 2026 introduction of a sterile glass cartridge solution for biologics in 3 mL and 5 mL formats.